Seguimento de dois anos em pacientes com hipertensão arterial pulmonar sob tratamento com sildenafila / Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil

FUNDAMENTO: Os efeitos de longo prazo das drogas desenvolvidas para o controle da hipertensão arterial pulmonar (HAP) são pouco conhecidos, já que os estudos multicêntricos em geral têm duração de 12 a 16 semanas. OBJETIVO: Avaliar a evolução de dois anos, em pacientes com HAP submetidos à monoterapia com sildenafila (inibidor da fosfodiesterase-5), com respeito à capacidade funcional. MÉTODOS: Vinte e quatro pacientes (idade entre 8 e 54 anos) com HAP idiopática (HAPI, n = 9) ou associada a cardiopatias congênitas (HAP-CCg, n = 15) foram tratados com sildenafila por dois anos, com doses diárias que variaram de 60 a 225 mg (três tomadas), por via oral. A capacidade física foi avaliada pela distância caminhada no teste de 6 minutos (DC6M) e pelo grau de dispneia ao final da caminhada (escala de Borg), sendo também registrada a saturação periférica de oxigênio (SpO(2)6M, oximetria de pulso). RESULTADOS: Nos 18 pacientes que completaram dois anos de seguimento, houve incremento progressivo e sustentado na DC6M, tanto no grupo HAPI (de 239 ± 160 m para 471 ± 66 m, p = 0,0076) como no grupo HAP-CCg (de 361 ± 144 m para 445 ± 96m, p = 0,0031), com melhora da dispneia ao final da caminhada (p < 0,05 em ambos). Não houve decréscimo na SpO(2)6M nos grupos considerados; em particular, pacientes com HAP-CCg evoluíram de 77 ± 20 por cento para 79 ± 16 por cento (p = 0,5248). Houve 5 óbitos (três no grupo HAPI) e uma perda de seguimento no período. CONCLUSÃO: Em dois anos de seguimento, a sildenafila mostrou-se útil no controle da condição funcional de pacientes com HAP, com melhora significante nas duas etiologias consideradas.

BACKGROUND: The long-term effects of drugs developed for the control of pulmonary arterial hypertension (PAH) are little known, since multicenter studies usually last 12 to 16 weeks. OBJECTIVE: To evaluate the two-year outcome of PAH patients receiving monotherapy with sildenafil (a phosphodiesterase-5 inhibitor), with regard to their functional capacity. METHODS: Twenty four patients (ages between 8 and 54 years) with idiopathic PAH (IPAH, n = 9) or congenital heart disease-associated PAH (CHD-PAH, n = 15) were treated with sildenafil for two years, with daily oral doses ranging from 60 to 225 mg (tid). Physical capacity was assessed by the distance walked in the 6-minute walk test (DW6M) and by the degree of dyspnea at the end of the walk (Borg scale); peripheral oxygen saturation was also recorded (SpO(2)6M, pulse oximetry). RESULTS: In the 18 patients who completed the two-year follow-up, there was a progressive and sustained increase in DW6M, both in the IPAH group (from 239 ± 160 m to 471 ± 66 m, p = 0.0076) and in the CHD-PAH group (from 361 ± 144 m to 445 ± 96m, p = 0.0031), with improvement of dyspnea at the end of the walk (p<0.05 for both groups). No decrease in SpO(2)6M was observed in the groups; in patients with CHD-PAH, in particular, SpO(2)6M went from 77 ± 20 percent to 79 ± 16 percent (p = 0.5248). Five deaths occurred (three in the IPAH group) and one patient was lost to follow-up during the study period. CONCLUSION: In a two-year follow-up, sildenafil proved useful in the control of the functional status of PAH patients, with significant improvement in both groups considered.

Ecocardiografia-doppler e parâmetros hemodinâmicos em cardiopatias congênitas com hiperfluxo pulmonar / Doppler echocardiography and hemodynamic parameters in congenital heart disease with increased pulmonary flow

FUNDAMENTO: A predição de dados de hemodinâmica pulmonar, a partir de avaliação não invasiva, poderia isentar alguns portadores de defeitos septais cardíacos congênitos da avaliação invasiva pré-operatória (cateterismo). OBJETIVO: Verificar, em avaliação simultânea, se dados obtidos pela ecocardiografia-Doppler poderiam predizer aspectos da condição hemodinâmica pulmonar em tais pacientes. MÉTODOS: Parâmetros ecocardiográficos relacionados ao fluxo sistólico pulmonar e sistêmico e ao fluxo em veia pulmonar foram relacionados a dados hemodinâmicos em 30 pacientes consecutivos com defeitos septais cardíacos (idade entre 4 meses e 58 anos, mediana 2,2 anos; pressão arterial pulmonar média entre 16 e 93 mmHg). RESULTADOS: As variáveis integral velocidade-tempo do fluxo sistólico em via de saída de ventrículo direito (VTI VSVD > 22 cm) e do fluxo em veia pulmonar (VTI VP > 20 cm) foram preditivos de níveis RVP/RVS <; 0,1 (relação entre resistências vasculares pulmonar e sistêmica), com especificidade de 0,81 e razão de chances acima de 1,0. Para valores VTI VSVD > 27 cm e VTI VP > 24 cm, a especificidade foi superior a 0,90 e a razão de chances 2,29 e 4,47 respectivamente. A razão entre os fluxos pulmonar e sistêmico (Qp/Qs > 2,89 e > 4,0, estimativas ecocardiográficas) foi útil na predição de valores Qp/Qs > 3,0 pelo cateterismo (especificidade de 0,78 e 0,91, razão de chances 1,14 e 2,97, respectivamente). CONCLUSÃO: Em portadores de defeitos septais cardíacos, a ecocardiografia-Doppler é capaz de identificar aqueles em situação de aumento de fluxo e baixos níveis de resistência vascular pulmonar.

BACKGROUND: The prediction of pulmonary hemodynamic data from non-invasive assessment could exempt some patients with congenital cardiac septal defects from preoperative invasive assessment (catheterization). OBJECTIVE: To determine, in simultaneous assessment, whether data obtained from Doppler echocardiography could predict aspects of pulmonary hemodynamics in such patients. METHODS: Echocardiographic parameters related to systolic and systemic pulmonary flow and pulmonary venous flow were related to hemodynamic data in 30 consecutive patients with cardiac septal defects (aged 4 months to 58 years, median 2.2 years, mean pulmonary artery pressure between 16 and 93 mmHg). RESULTS: The velocity-time integrals of systolic flow in right ventricle outflow tract (VTI RVOT > 22 cm) and pulmonary venous flow (VTI VP > 20 cm) predicted PVR/SVR <; 0.1 levels (pulmonary vascular resistance and systemic vascular resistance ratio), with a specificity of 0.81 and odds ratio above 1.0. For VTI RVOT > 27 cm and VTI PV > 24 cm values, the specificity was higher than 0.90 and odds ratio 2.29 and 4.47 respectively. The ratio between pulmonary and systemic flows (Qp/Qs > 2.89 and > 4.0, echocardiographic estimates) was useful in predicting Qp/Qs > 3.0 values through catheterization (specificity of 0.78 and 0.91, odds ratio 1.14 and 2.97, respectively). CONCLUSION: In patients with cardiac septal defects, Doppler echocardiography is able to identify those at increased flow and low pulmonary vascular resistance.

[Doppler echocardiography and hemodynamic parameters in congenital heart disease with increased pulmonary flow]. / Ecocardiografia-Doppler e parâmetros hemodinâmicos em cardiopatias congênitas com hiperfluxo pulmonar.

BACKGROUND: The prediction of pulmonary hemodynamic data from non-invasive assessment could exempt some patients with congenital cardiac septal defects from preoperative invasive assessment (catheterization). OBJECTIVE: To determine, in simultaneous assessment, whether data obtained from Doppler echocardiography could predict aspects of pulmonary hemodynamics in such patients. METHODS: Echocardiographic parameters related to systolic and systemic pulmonary flow and pulmonary venous flow were related to hemodynamic data in 30 consecutive patients with cardiac septal defects (aged 4 months to 58 years, median 2.2 years, mean pulmonary artery pressure between 16 and 93 mmHg). RESULTS: The velocity-time integrals of systolic flow in right ventricle outflow tract (VTI RVOT > or = 22 cm) and pulmonary venous flow (VTI VP > or = 20 cm) predicted PVR/SVR <; 0.1 levels (pulmonary vascular resistance and systemic vascular resistance ratio), with a specificity of 0.81 and odds ratio above 1.0. For VTI RVOT > or = 27 cm and VTI PV > 24 cm values, the specificity was higher than 0.90 and odds ratio 2.29 and 4.47 respectively. The ratio between pulmonary and systemic flows (Qp/Qs > 2.89 and > or = 4.0, echocardiographic estimates) was useful in predicting Qp/Qs > 3.0 values through catheterization (specificity of 0.78 and 0.91, odds ratio 1.14 and 2.97, respectively). CONCLUSION: In patients with cardiac septal defects, Doppler echocardiography is able to identify those at increased flow and low pulmonary vascular resistance.

[Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil]. / Seguimento de dois anos em pacientes com hipertensão arterial pulmonar sob tratamento com sildenafila.

BACKGROUND: The long-term effects of drugs developed for the control of pulmonary arterial hypertension (PAH) are little known, since multicenter studies usually last 12 to 16 weeks. OBJECTIVE: To evaluate the two-year outcome of PAH patients receiving monotherapy with sildenafil (a phosphodiesterase-5 inhibitor), with regard to their functional capacity. METHODS: Twenty four patients (ages between 8 and 54 years) with idiopathic PAH (IPAH, n = 9) or congenital heart disease-associated PAH (CHD-PAH, n = 15) were treated with sildenafil for two years, with daily oral doses ranging from 60 to 225 mg (tid). Physical capacity was assessed by the distance walked in the 6-minute walk test (DW6M) and by the degree of dyspnea at the end of the walk (Borg scale); peripheral oxygen saturation was also recorded (SpO(2)6M, pulse oximetry). RESULTS: In the 18 patients who completed the two-year follow-up, there was a progressive and sustained increase in DW6M, both in the IPAH group (from 239 +/- 160 m to 471 +/- 66 m, p = 0.0076) and in the CHD-PAH group (from 361 +/- 144 m to 445 +/- 96 m, p = 0.0031), with improvement of dyspnea at the end of the walk (p<0.05 for both groups). No decrease in SpO(2)6M was observed in the groups; in patients with CHD-PAH, in particular, SpO(2)6M went from 77 +/- 20% to 79 +/- 16% (p = 0.5248). Five deaths occurred (three in the IPAH group) and one patient was lost to follow-up during the study period. CONCLUSION: In a two-year follow-up, sildenafil proved useful in the control of the functional status of PAH patients, with significant improvement in both groups considered.

O ecocardiograma como preditor de variáveis hemodinâmicas nas cardiopatias congênitas com hipertensão pulmonar e nos candidatos a transplante cardíaco / Echocardiographyc estimates of hemodynamic parameters in pulmonary hypertension associated with congenital cardiac shunts or cardiomyopathy

A condição de hipertensão pulmonar é definida como a presença de pressão arterial pulmonar média acima de 25 mmHg em repouso. Esta é a resultante hemodinâmica de vários processos nosológicos que acometem a circulação nos pulmões, notadamente os pequenos vasos pré e intra-acinares. A microcirculação pulmonar pode se alterar na presença de enfermidades cardíacas, pulmonares, tromboembólicas, infecto-parasitárias e do tecido conectivo, entre outras. Na ausência dessas condições, o diagnóstico de hipertensão arterial pulmonar idiopática se impõe. Com respeito especificamente à doença cardíaca levando a alterações vasculares pulmonares, temos as situações que acarretam aumento de fluxo sangüíneo pulmonar (cardiopatias congênitas que cursam com defeitos de septação das câmaras ou dos grandes vasos) ou dificuldade de drenagem venosa (disfunção sistólica ou diastólica do ventrículo esquerdo, valvopatia mitral e doenças do átrio esquerdo ou veias pulmonares). As alterações vasculares pulmonares que ocorrem nessas circunstâncias podem dificultar ou impedir o reparo cirúrgico de um defeito congênito de septação cardíaca, ou o encaminhamento de pacientes com doença miocárdica para o transplante. Por essas razões, a avaliação de pacientes com defeitos septais cardíacos ou miocardiopatia deve ser criteriosa. Na maioria das vezes a avaliação não invasiva é suficiente para o planejamento terapêutico. Entretanto, em pacientes com cardiopatia congênita e suspeita clínica de hipertensão pulmonar, assim como naqueles portadores de miocardiopatia candidatos ao transplante, a medida direta da resistência vascular pulmonar, através de procedimento invasivo, se faz necessária. Nas últimas décadas, tem havido interesse progressivo de se ampliar a indicação da avaliação não invasiva, omitindo-se a invasiva, sobretudo com o uso de parâmetros avaliados pela ecocardiografia com Doppler e pela ressonância magnética. O uso dessas medidas, na prática clínica, ainda é restrito...

Pulmonary hypertension is defined as a mean pulmonary arterial pressure of > 25 mmHg registered at rest, during cardiac catheterization. A number of conditions have been demonstrated to cause pulmonary hypertension, including congenital (septal defects) and acquired heart diseases, chronic lung disease, connective-tissue disease, thromboembolic disorders, schistosomosiasis, HIV infection, use of anorexigens, etc. In the absence of all these conditions, a diagnosis of idiopathic pulmonary arterial hypertension is established. In the specific setting of the cardiac disorders, either increased pulmonary blood flow (congenital cardiac septal defects) or altered pulmonary venous drainage (left ventricular systolic or diastolic dysfunction, mitral valve disease, abnormalities of the left atrium) can cause pulmonary vascular abnormalities leading to pulmonary hypertension. Moderate to severe pulmonary vascular abnormalities lead to increased risk of postoperative complications and/or poor long-term outcomes in patients with septal defects undergoing surgical repair or those with cardiomyopathy undergoing heart transplantation. Thus, for these patients, preoperative measurement of pulmonary vascular resistance by cardiac catheterization is mandatory. In general, those with a pulmonary vascular resistance index of > 6 Wood units·m2 (pulmonary to systemic vascular resistance ratio of > 0,3) are not assigned to operation. In the last decades, there has been growing interest on the development of noninvasive methods/parameters that could allow for decision about the therapeutic strategies without cardiac catheterization. In this way, several parameters derived from Doppler-echocardiographic analysis or magnetic resonance has been used to predict hemodynamic data. In the present study, we used echocardiographic parameters to determine which patients with congenital cardiac septal defects...